Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
263 hedge funds and large institutions have $4.43B invested in Apellis Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 127 increasing their positions, 66 reducing their positions, and 67 closing their positions.
359% more call options, than puts
Call options by funds: $230M | Put options by funds: $50M
92% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 66
1.3% more ownership
Funds ownership: 93.81% → 95.11% (+1.3%)
13% less funds holding
Funds holding: 302 → 263 (-39)
33% less capital invested
Capital invested by funds: $6.65B → $4.43B (-$2.22B)
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
52% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$67.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$60.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$56M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$50.8M |
| 5 |
JP Morgan Chase
New York
|
+$43.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$58.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$53.6M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$52M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$46.7M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$37.1M |
APLS Hedge Fund Activity: Q2 2024 in Review
263 of the 6,930 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2024, worth a combined $4.43B — down 33% from $6.65B a quarter earlier.
Sellers outnumbered buyers: 67 funds closed out of APLS and 32 opened new positions — a net loss of 35 holders — while 66 trimmed existing stakes and 127 added.
The largest buyer was Deep Track Capital, adding an estimated $67.9M. The largest seller was Assenagon Asset Management, cutting an estimated $58.4M.
- 263 institutional investors held Apellis Pharmaceuticals (APLS) as of Q2 2024, down from 302 in Q1 2024.
- Funds reported $4.43B of Apellis Pharmaceuticals stock for Q2 2024, down 33% quarter-over-quarter.
- 32 funds opened new Apellis Pharmaceuticals positions in Q2 2024 and 67 closed out, a net change of -35 holders.
- The largest Apellis Pharmaceuticals buyer in Q2 2024 was Deep Track Capital, an estimated $67.9M added.
- The largest Apellis Pharmaceuticals seller in Q2 2024 was Assenagon Asset Management, an estimated $58.4M sold.
Based on aggregated 13F filings for Q2 2024.